Universal reference book for medicines
Product name: CEREPRO (CEREPRO)

Active substance: choline alfoscerate

Type: Nootropic drug.
Holinomimetics of central action
Manufacturer: VEROPHARM (Russia)
Composition, form of production and packaging
The solution for intravenous and / or injection is clear, colorless.
1 ml of 1 amp.
choline alfoscerate (glycerylphosphoryl choline hydrate) 250 mg 1 g
Auxiliary substances: water d / u - up to 1 ml.
4 ml - ampoules (3) - packings of cellular contour (1) - packs cardboard.
4 ml - ampoules (5) - packings of cellular contour (1) - cardboard boxes.
Description of the drug approved by the manufacturer for the printed edition of 2013.
Holinomimetics of central action, which contains 40.5% of metabolically protected choline (metabolic protection contributes to the release of choline in the brain). Upon ingestion, it is cleaved under the action of enzymes on choline and glycerophosphate: choline participates in the biosynthesis of acetylcholine, one of the main neurotransmitter mediators; glycerophosphate is a precursor of phospholipids (phosphatidylcholine) neuronal membrane. The drug provides the synthesis of acetylcholine and phosphatidylcholine in neuronal membranes, improves blood flow and enhances metabolic processes in the central nervous system, activates the reticular formation; increases the linear velocity of blood flow on the side of traumatic brain injury, contributes to the normalization of spatiotemporal characteristics of spontaneous bioelectrical activity of the brain; has a positive effect on the cognitive and behavioral responses of patients with cerebral vascular diseases.
The drug improves brain function, affecting the pathogenetic factors of the involutionary psychoorganic syndrome, changes the phospholipid composition of neuronal membranes and reduces cholinergic activity. Dosolependently stimulates the release of acetylcholine, participating in the synthesis of phosphatidylcholine (membrane phospholipid), improves synaptic transmission, plasticity of neuronal membranes, receptor function.
Suction and distribution
After ingestion, absorption is 88%.
Easily penetrates through the BBB (with oral intake, the concentration in the brain reaches 45% of the level in the blood plasma).
It is produced mainly by light ones in the form of carbon dioxide (85%); The remaining part (15%) is excreted in urine and feces.
- acute and recovery periods of severe craniocerebral trauma (including in cases of impaired consciousness, coma);
- disorders of cerebral circulation according to the ischemic type (acute and recovery period) and hemorrhagic type (recovery period), occurring with focal hemispheric symptoms or symptoms of brain stem damage;
- psycho-organic syndrome on the background of degenerative and involuntary changes in the brain and the consequences of cerebrovascular insufficiency;
- Cognitive impairment (impaired mental function, memory, confusion, disorientation, decreased motivation, initiative and ability to concentrate), incl. with dementia and encephalopathy;
- senile pseudomelanchia, changes in the emotional and behavioral sphere: emotional lability, increased irritability, decreased interest.
The drug is administered in / m in a dose of 1 g (1 ampoule) / day or iv (slowly) at a dose of 1 g to 3 g / day.
With iv administration, the contents of 1 ampoule (4 ml) are diluted in 50 ml of physiological solution, the infusion rate is 60-80 drops / min.
Duration of treatment is 10-15 days, but if necessary, the treatment can be continued until the appearance of positive dynamics and the ability to switch to taking capsules.
From the side of the digestive system: nausea (as a consequence of dopaminergic activation).
Other: allergic reactions.
- Pregnancy;
- the period of lactation (breastfeeding);
- Hypersensitivity to the components of the drug.
With caution should be used in children and adolescents under 18 years (due to lack of data on the effectiveness and safety of the drug).
The drug is contraindicated for use in pregnancy and lactation (breastfeeding).
In experimental studies, there was no mutagenic and teratogenic effect of the drug, as well as an effect on reproductive functions.
With caution should be used in children and adolescents under 18 years (due to the lack of data on the effectiveness and safety of the drug)
If there is nausea after taking the drug should reduce the dose.
Impact on the ability to drive vehicles and manage mechanisms
Cerepro does not affect the speed of psychomotor reactions.
Symptoms: indigestion.
Treatment: gastric lavage, reception of activated charcoal, symptomatic therapy.
The drug interaction of Cerepro is not established.
The drug is released by prescription.
The drug should be stored in a place protected from light and inaccessible to children at a temperature of no higher than 25 ° C. Shelf life - 2 years.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!